Co-Authors
This is a "connection" page, showing publications co-authored by MYRNA GODOY and JUNYA FUJIMOTO.
Connection Strength
0.382
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.056
-
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2021 May 12; 12(1):2888.
Score: 0.049
-
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 2021 05 11; 12(1):2722.
Score: 0.049
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.048
-
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun. 2021 01 29; 12(1):687.
Score: 0.048
-
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
Score: 0.045
-
Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
Score: 0.045
-
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2019 07 05; 10(1):2978.
Score: 0.043